Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention.
Adolescent
Adult
Aged
Cytochrome P-450 CYP2C19
/ genetics
Drug Prescriptions
/ statistics & numerical data
Follow-Up Studies
Humans
Incidence
Middle Aged
Percutaneous Coronary Intervention
/ adverse effects
Pharmacogenomic Testing
Pharmacogenomic Variants
Postoperative Complications
/ drug therapy
Precision Medicine
/ methods
Young Adult
Journal
Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
28
08
2019
accepted:
02
11
2019
pubmed:
24
11
2019
medline:
7
8
2021
entrez:
24
11
2019
Statut:
ppublish
Résumé
We aimed to estimate the utility of panel-based pharmacogenetic testing of patients undergoing percutaneous coronary intervention (PCI). Utilization of Clinical Pharmacogenetic Implementation Consortium (CPIC) level A/B drugs after PCI was estimated in a national sample of IBM MarketScan beneficiaries. Genotype data from University of Florida (UF) patients (n = 211) who underwent PCI were used to project genotype-guided opportunities among MarketScan beneficiaries with at least one (N = 105,547) and five (N = 12,462) years of follow-up data. The actual incidence of genotype-guided prescribing opportunities was determined among UF patients. In MarketScan, 50.0% (52,799/105,547) over 1 year and 68.0% (8,473/12,462) over 5 years had ≥ 1 CPIC A/B drug besides antiplatelet therapy prescribed, with a projected incidence of genotype-guided prescribing opportunities of 39% at 1 year and 52% at 5 years. Genotype-guided prescribing opportunities occurred in 32% of UF patients. Projected and actual incidence of genotype-guided opportunities among two cohorts supports the utility of panel-based testing among patients who underwent PCI.
Identifiants
pubmed: 31758664
doi: 10.1111/cts.12729
pmc: PMC7214641
doi:
Substances chimiques
CYP2C19 protein, human
EC 1.14.14.1
Cytochrome P-450 CYP2C19
EC 1.14.14.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
473-481Subventions
Organisme : NHGRI NIH HHS
ID : U01 HG007269
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001427
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000064
Pays : United States
Informations de copyright
© 2019 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.
Références
Clin Pharmacol Ther. 2017 Jul;102(1):37-44
pubmed: 27997040
CMAJ Open. 2015 Apr 02;3(2):E166-71
pubmed: 26389094
Clin Transl Sci. 2017 May;10(3):143-146
pubmed: 28294551
Pharmacogenomics. 2017 Apr;18(5):421-426
pubmed: 28346068
Clin Pharmacol Ther. 2008 May;83(5):781-7
pubmed: 18253145
Clin Pharmacol Ther. 2015 Aug;98(2):127-34
pubmed: 25974703
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934
pubmed: 24239923
J Mol Diagn. 2016 May;18(3):438-445
pubmed: 26947514
Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):56-67
pubmed: 24616371
JAMA Netw Open. 2019 Jun 5;2(6):e195345
pubmed: 31173123
PLoS One. 2015 Jan 27;10(1):e0113808
pubmed: 25625348
Genet Med. 2019 Oct;21(10):2255-2263
pubmed: 30894703
Am J Health Syst Pharm. 2016 Dec 1;73(23):1944-1954
pubmed: 27864202
Clin Pharmacol Ther. 2011 May;89(5):662-73
pubmed: 21412232
Genet Test Mol Biomarkers. 2019 Mar;23(3):209-214
pubmed: 30758238
Mayo Clin Proc. 2014 Jan;89(1):25-33
pubmed: 24388019
Circulation. 2017 Nov 14;136(20):1955-1975
pubmed: 29084738
J Pharm Sci. 2017 Sep;106(9):2368-2379
pubmed: 28619604
Clin Pharmacol Ther. 2014 Apr;95(4):376-82
pubmed: 24458010
Clin Pharmacol Ther. 2012 Oct;92(4):414-7
pubmed: 22992668
Clin Pharmacol Ther. 2011 Mar;89(3):464-7
pubmed: 21270786
Clin Pharmacol Ther. 2018 May;103(5):778-786
pubmed: 29460415
Drug Saf. 2017 Jan;40(1):65-80
pubmed: 27638658
J Transl Med. 2018 Apr 11;16(1):92
pubmed: 29642909
Annu Rev Pharmacol Toxicol. 2015;55:89-106
pubmed: 25292429
Nat Biotechnol. 2006 Apr;24(4):403-10
pubmed: 16601719
Clin Pharmacol Ther. 2017 Sep;102(3):502-510
pubmed: 28090649
Drug Saf. 2017 Jan;40(1):1-2
pubmed: 27873192
Clin Pharmacol Ther. 2014 Apr;95(4):423-31
pubmed: 24253661
JACC Cardiovasc Interv. 2012 Dec;5(12):1195-208
pubmed: 23257367
Heart. 2017 Nov;103(22):1800-1805
pubmed: 28689179